PDCD1 and head and neck squamous cell carcinoma: In patients with R/M HNSCC who progressed during or after platinum chemotherapy, treatment with the programmed cell death 1 (PD-1) inhibitors pembrolizumab and nivolumab increased overall survival compared to conventional therapy (29, 33).